HepaStem
Phase 2Small molecule
HepaStem is one of 16 small molecule programs targeting Chronic Liver Failure. It is currently in Phase 2.
2
Indications
6
Total Trials
0
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
28 competitors in Chronic Liver Failure
#DrugCompanyPhaseTrials
1Mozobil
GGenzyme, a Sanofi Company
Approved
Tenofovir (TFV) IVR
GileadApproved
Soliris
AstraZenecaPhase 1
Vastarel
IIRCCS San Raffaele
Phase 1
Viread
GSKPreclinical
HepaStem
CCellaion SA
Phase 2
Osmitrol
BB. Braun Medical Inc.
Preclinical
Glypressin
MMallinckrodt
Preclinical
Coreg
Akero TherapeuticsPreclinical
Chronulac
SSolvay Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Urea Cycle Disorders2 trials
Chronic Liver Failure1 trial
NASH1 trial
Crigler-Najjar syndrome1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HepaStem. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- CCellaion SA